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Abstract 
Background: Eradication of HIV cannot be achieved with combination antiretroviral therapy (cART) because of the 
persistence of long-lived latently infected resting memory CD4+ T cells. We previously reported that HIV latency could 
be established in resting CD4+ T cells in the presence of the chemokine CCL19. To define how CCL19 facilitated the 
establishment of latent HIV infection, the role of chemokine receptor signalling was explored.
Results: In resting CD4+ T cells, CCL19 induced phosphorylation of RAC-alpha serine/threonine-protein kinase (Akt), 
nuclear factor kappa B (NF-κB), extracellular-signal-regulated kinase (ERK) and p38. Inhibition of the phosphoinositol-
3-kinase (PI3K) and Ras/Raf/Mitogen-activated protein kinase/ERK kinase (MEK)/ERK signalling pathways inhibited HIV 
integration, without significant reduction in HIV nuclear entry (measured by Alu-LTR and 2-LTR circle qPCR respec-
tively). Inhibiting activation of MEK1/ERK1/2, c-Jun N-terminal kinase (JNK), activating protein-1 (AP-1) and NF-κB, but 
not p38, also inhibited HIV integration. We also show that HIV integrases interact with Pin1 in CCL19-treated CD4+ T 
cells and inhibition of JNK markedly reduced this interaction, suggesting that CCL19 treatment provided sufficient sig-
nals to protect HIV integrase from degradation via the proteasome pathway. Infection of CCL19-treated resting CD4+ 
T cells with mutant strains of HIV, lacking NF-κB binding sites in the HIV long terminal repeat (LTR) compared to infec-
tion with wild type virus, led to a significant reduction in integration by up to 40-fold (range 1–115.4, p = 0.03). This 
was in contrast to only a modest reduction of 5-fold (range 1.7–11, p > 0.05) in fully activated CD4+ T cells infected 
with the same mutants. Finally, we demonstrated significant differences in integration sites following HIV infection of 
unactivated, CCL19-treated, and fully activated CD4+ T cells.
Conclusions: HIV integration in CCL19-treated resting CD4+ T cells depends on NF-κB signalling and increases the 
stability of HIV integrase, which allow subsequent integration and establishment of latency. These findings have impli-
cations for strategies needed to prevent the establishment, and potentially reverse, latent infection.
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Background
The major barrier to HIV cure in patients receiving com-
bination antiretroviral therapy (cART) is the persistence 
of long-lived, latently infected, resting memory CD4+ T 
cells [1]. Understanding how HIV latency is established 
and maintained is critical to the development of novel 
approaches to eradicate HIV. Direct infection of rest-
ing CD4+ T cells in vitro is inefficient [2, 3]. In contrast, 
HIV integration and latency is established in resting 
CD4+ T cells in  vivo [4], in tonsil explants [5], or fol-
lowing co-culture with endothelial cells [6] or dendritic 
cells [7], or following culture with chemokines that bind 
to the chemokine receptors CCR7, CXCR3 and CCR6 
expressed on resting CD4+ T cells [8, 9].
The chemokine CCR7 is expressed on naïve and cen-
tral memory CD4+ T cells and culturing with the CCR7-
ligands CCL19 or CCL21 facilitates entry and integration 
of HIV into these resting CD4+ T cells with minimal 
virus production. In this model, resting CD4+ T cells 
5  day post infection represent a stable latently infected 
population that respond to latency-reversing agents 
(LRA) in a similar pattern to CD4+ T cells from HIV-
infected individuals on cART [10]. We therefore believe 
this is an ideal model to study the early events required 
for establishing latency.
Binding of chemokines to their specific Gi-coupled 
receptors leads to activation of the RhoA/GTPase, phos-
phatidylinositol 3-kinase (PI3K) and phospholipase C 
(PLC) pathways [11]. Binding of HIV glycoprotein (gp)120 
to the HIV co-receptor CXCR4 can also activate the RhoA 
pathway in resting CD4+ T cells, activating cofilin leading 
to depolymerization of the cortical actin cytoskeleton, 
thus facilitating nuclear entry [3, 12]. We demonstrated 
similar cellular changes with the exogenous chemokine 
CCL19 [9]. However, in contrast to HIV infection of rest-
ing CD4+ T cells, where there is minimal integration of 
HIV [2, 3, 9], in chemokine treated cells there was effi-
cient nuclear localization and HIV integration [8, 9].
Activation of PI3K leads to changes in nuclear factor 
kappa B (NF-κB), the Mitogen-Activated Protein kinases 
(MAPK), extra-cellular signal-regulated kinases 1 and 2 
(ERK1/2) [13], p38, c-Jun N-terminal kinase (JNK) [14] 
and serine/threonine protein kinase (Akt) phosphoryla-
tion (Additional file  1: Figure S1). Although NF-κB is a 
potent activator of HIV transcription, previous studies 
have demonstrated that latent or productive infection 
may depend on the relative amount of active NF-κB. In 
T cell lines, high levels of NF-κB enhance HIV transcrip-
tion, but low levels of NF-κB are important for HIV inte-
gration [15]. Furthermore, generating latent infection by 
direct infection of Jurkat T cells requires low levels of 
NF-κB [16]. However, the role of NF-κB in latency in pri-
mary resting CD4+ T cells remains unknown.
Other downstream signalling products of chemokine 
receptor signalling may also impact HIV integration and 
latent infection of resting CD4+ T cells. Activating pro-
tein-1 transcription factors (AP-1) [17] may play a role in 
establishing and maintaining HIV latency [18]. The Ras/
Raf/MEK pathway has previously been associated with 
the nuclear import of the HIV reverse transcriptase com-
plex (RTC) [19] and thus may enhance HIV nuclear entry 
required for infection of resting CD4+ T cells. In the pre-
sent study, we asked whether the PI3K signalling pathway, 
induced by ligation of CCL19 to CCR7, played a key role 
in the establishment of latent infection in CCL19-treated 
resting CD4+ T cells. We demonstrated that activation of 
the NF-κB pathway is critical for efficient integration of 
HIV in CCL19-treated resting CD4+ T cells and that the 
sites of HIV integration depended on the activation state 
of the cell at the time of infection.
Results
Dose response of CCL19 on resting CD4+ T cell signalling
We first determined the dose response of CCL19 on 
activation of downstream signalling in resting CD4+ 
T cells. After only 5  min of treatment with CCL19, we 
saw a strong increase in the level of phosphorylated Akt 
and NF-κB with all doses (range 30–300 nM) of CCL19 
(Additional file  2: Figure S2A). However, we observed a 
dose response of CCL19 on the level of phosphorylated 
ERK. We believe that this may be due to different kinetic 
of activation. Indeed, treatment of resting CD4+ T cells 
with various doses of CCL19 for 15 min led to phospho-
rylation of Akt, NF-κB, ERK and low levels of JNK (Addi-
tional file 2: Figure S2B). Since very low levels of CCL19 
(10–100  nM) are required for priming of resting CD4+ 
T cells for latent infection with HIV [8], we used 30 and 
100 nM of CCL19 for subsequent infection and immuno-
blotting experiments, respectively.
Inhibition of CCL19‑induced signalling by pharmacological 
inhibitors
Activation of CCR7 has been shown to induce multiple 
modules of signalling leading to cell survival, chemot-
axis, endocytosis and others (see review in [11, 20]). To 
determine which pathway of CCL19-mediated signalling 
was important for establishment of latency, pharmaco-
logical agents that inhibit various signalling molecules 
were used (Additional file  1: Figure S1). Inhibition of 
CCL19-induced phosphorylation of Akt, NF-κB, ERK 
and p38 were observed using specific inhibitors to PI3K 
(LY294002 and Wortmannin), NF-κB (SC-514) (Fig.  1a, 
c-I, c-II); MEK1/ERK1/2 (PD980509), p38 (SB203580) 
(Fig.  1b, c-III, c-IV); and a broad-spectrum inhibitor of 
Akt and NF-κB (Bay11-7082) (Fig. 1a, c-II). Phosphoryla-
tion of JNK was not consistently observed in response to 
Page 3 of 12Saleh et al. Retrovirology  (2016) 13:49 
Fig. 1 Inhibition of the CCL19-mediated signalling by pharmacological inhibitors. Resting CD4+ T cells were treated for 1 h with a predetermined 
(see “Methods”) concentration of inhibitor to PI3K (LY294002 and Wortmannin), NF-κB (Bay11-7082 and SC-514), JNK (SP600125), ERK (PD980509), 
AP-1 (SR11302) and p38 (SB203580) prior to the addition of CCL19 (100 nM) for 15 min. Cells were lysed and the level of specific phosphorylated 
proteins was measured using immunoblotting. a, b Representative immunoblots from two different donors treated with various inhibitors. GAPDH 
immunoblot was used as control for equal protein loading. c Densitometry of various phosphorylated proteins in the presence or absence of inhibi-
tors in CCL19-treated resting CD4+ T cells. Values were normalised to both GAPDH and unactivated control. Data represent mean ± SD from 2 to 3 
experiments
Page 4 of 12Saleh et al. Retrovirology  (2016) 13:49 
CCL19. Since phosphorylation of JNK is required for cell 
migration [21], the lack of pJNK in CCL19-treated cells is 
likely due to timing of detection, as CD4+ T cell migra-
tion is normally measured at least 3 h after the addition 
of CCL19 [22]. However, the effect of JNK (SP600125) 
and AP-1 (SR11302) inhibitors on CCL19-treated cells 
were indirectly observed (Fig.  1c). SP600125 markedly 
inhibited phosphorylation of Akt, but increased p38 
phosphorylation, while SR11302 inhibited the phospho-
rylation of both ERK and p38.
As expected, specific inhibition of PI3K (LY294002 and 
Wortmannin) and NF-κB activation (SC-514) had mini-
mal effect on CCL19-mediated phosphorylation of ERK 
and p38 (Fig.  1a). Similarly, inhibition of the Ras/Raf/
MEK signalling pathway had minimal effects on phos-
phorylation of Akt and NF-κB (Fig.  1b), demonstrating 
the dichotomy of these two pathways in CCR7-signalling.
CCL19‑mediated HIV integration is restricted by inhibitors 
of both PI3K and Ras/Raf/MEK signalling pathways
We used inhibitors of the PI3K pathway, to determine if 
activation of this pathway was critical for HIV integration 
in CCL19-treated resting CD4+ T cells (Fig. 2). In HIV-
infected CCL19-treated resting CD4+ T cells, treatment 
of cells prior to infection with the inhibitors of PI3K, 
LY294002 and Wortmannin, significantly reduced HIV 
integration as measured by Alu-LTR PCR, and reduced 
the levels of 2-LTR circles back to the level of unactivated 
cells (Fig. 2b, c).
To define the specific pathways downstream of the 
chemokine receptor important for HIV integration, we 
next tested inhibitors of p38, MEK1/ERK1/2, JNK, AP-1 
and NF-κB, prior to infection of CCL19-treated resting 
CD4+ T cells. HIV integration was reduced to undetect-
able levels in the presence of inhibitors to MEK1/ERK1/2, 
JNK, AP-1 and NF-κB (Fig.  2d). In comparison, the p38 
inhibitor SB203580 had a mild inhibitory (but not signifi-
cant) effect on HIV integration (Fig. 2d), despite being able 
to fully inhibit p38 phosphorylation (Fig. 1). These inhibi-
tors also reduced the level of 2-LTR circles back to unac-
tivated cells level, although the reduction did not reach 
statistical significance (Fig. 2e). The effect of these inhibi-
tors on HIV integration and 2-LTR circles were not likely 
due to the cytotoxicity of these drugs (Additional file  3: 
Figure S3). We found that the broad-spectrum inhibitor 
of Akt and NF-κB, Bay11-7082, was highly toxic to resting 
CD4+ T cells and was removed from further analysis.
Pin1 is a cellular factor required for HIV integration 
in CCL19‑treated cells
Since JNK activation phosphorylates and stabi-
lizes HIV integrase via an interaction with peptidyl 
Fig. 2 Treatment with PI3K and Ras/Raf/MEK inhibitors, eliminates 
HIV integration in CCL19-treated resting CD4+ T cells. a Resting CD4+ 
T-cells were pre-incubated with inhibitors of specific signalling path-
ways for 1 h before addition of CCL19, PHA-IL2 or DMSO and then 
infected with HIV NL4-3 for 2 h and cultured with media containing 
IL2 (1 U/mL) for up to 4 days following infection. HIV integration was 
measured by qPCR for Alu-LTR (b, d) and nuclear entry was measured 
by qPCR for 2-LTR circles (c, e). Experiments were also performed in 
the presence of inhibitors to PI3K (LY294002 and Wortmannin; b, c). d, 
e Further experiments were conducted in the presence of inhibi-
tors of p38 (SB203580), ERK1/2 (PD980509), JNK (SP600125), AP-1 
(SR11302), or NF-κB (SC-514) activation. Each column represents the 
mean copy number and the symbols represent individual donors. The 
detection limit for the Alu-LTR was 300 copies/106 cells and is shown 
as a dashed line. *p < 0.05; **p < 0.005
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prolyl-isomerase (Pin1) in activated CD4+ T cells [23], 
we used a co-immunoprecipitation (IP) assay to analyse 
the formation of Pin1/integrase-containing complexes in 
resting CCL19-treated CD4+ T cells. Like PHA-IL2 acti-
vation, CCL19 induced formation of Pin1/integrase com-
plexes and this was impaired in the presence of the JNK 
inhibitor SP600125 (Fig. 3a). We also used siRNA knock-
down of Pin1 to determine whether Pin1 was required 
for integration and establishment of latency in CCL19-
treated resting CD4+ T cells. Expression of Pin1 in CD4+ 
T cells was similar after stimulation with PHA-IL2 or 
CCL19, but was greatly reduced in siRNA-transfected 
cells compared to the scrambled control (Fig. 3b, upper 
panel). Following HIV infection of these cells, we found 
a statistically significant reduction in both 2-LTR circles 
and integrated HIV DNA (Fig. 3b), consistent with a pre-
vious report [23]. These data suggest that Pin1 may affect 
pre-integration events in resting CD4+ T cells as well as 
PHA-IL2 activated cells. These experiments confirmed 
that interactions of JNK, integrase and Pin1 are likely 
similar following infection of resting and activated CD4+ 
T cells and are critical for HIV infection.
NF‑κB site 1 in the HIV LTR is essential for HIV integration 
in CCL19‑treated resting CD4+ T cells
To determine the role of NF-κB in the establishment of 
latency, we next infected CCL19-treated resting CD4+ T cells 
with HIV that contained a mutation in one or both NF-κB 
binding sites in the HIV LTR, which we refer to as ΔNF-κB1, 
ΔNF-κB2 or ΔNF-κB1,B2 respectively (Fig. 4a). No integra-
tion was detected after infection of CCL19-treated resting 
CD4+ T cells with NL4-3 ΔNF-κB1 or ΔNF-κB1,B2 (Fig. 4b), 
highlighting the critical role of the first NF-κB site in facilitat-
ing HIV integration in CCL19-treated resting CD4+ T cells. 
Infection with NL4-3 ΔNF-κB1,B2, compared to wild type 
NL4-3, showed a decreased in HIV integration to undetect-
able levels in all 4 donors by a mean (range) of 40 (1–115.4) 
fold (p = 0.03) in CCL19-treated CD4+ T cells with only a 
modest reduction in HIV integration of 5 (1.7–11) fold in 
fully activated CD4+ T cells although this was not significant. 
Similar results were obtained following infection with the 
ΔNF-κB1 single mutant when compared to wild type NL4-3. 
Infection with the ΔNF-κB2 single mutant showed a reduc-
tion in integration in CCL19-treated CD4+ T cells in only 
two of the 4 donors tested (Fig. 4b). In contrast, infection of 
PHA-IL2 activated CD4+ T cells resulted in a small but non 
statistically significant reduction in the levels of integration 
following infection with NL4-3 ΔNF-κB1 and ΔNF-κB1,B2 
viruses (Fig. 4b).
In unactivated resting CD4+ T cells, integration 
was not detected (<300 copies/million cells, n  =  4) for 
all viruses tested, except one donor where infection 
with NL4-3 wild type virus had detectable integration 
(Fig.  4b). There were no significant changes in the fre-
quency of 2-LTR circles in the different culture condi-
tions when the different mutant viruses were compared 
to wild type NL4-3 (Fig.  3c). Collectively, these data 
demonstrate that at least the first NF-κB binding site in 
the HIV LTR is required for efficient HIV integration in 
CCL19-treated resting CD4+ T cells.
Identification of HIV integration sites in resting 
and activated CD4+ T cells
Given the importance of intact NF-κB sites for integra-
tion in CCL19-treated resting CD4+ T cells, we next 
asked if the site of HIV integration differed when HIV 
Fig. 3 Role of Pin1 in HIV integration in CCL19-treated resting CD4+ 
T cells. Resting CD4+ T cells were cultured with CCL19 or activated 
with PHA-IL2 for 2 days prior to infection with HIV NL4-3. Immuno-
precipitated proteins were analysed by SDS-PAGE and immunoblot 
with anti-HIV integrase antibody. a Co-IP of integrase and Pin1 was 
determined by IP with anti-Pin1 antibodies and probing for integrase 
(32 kDa) and Pin1 (18 kDa) in the presence and absence of the JNK 
inhibitor (SP600125, 10 µM) in HIV-infected CCL19-treated (upper 
panel) and PHA-IL2 activated (lower panel) CD4+ T cells. b PHA-IL2 
activated and CCL19-treated resting CD4+ T cells were transfected 
with Pin1-specific or scrambled control siRNA, infected 2 days later 
with HIV, and 5 h later examined for Pin1 expression by immuno-
blot with antibodies to Pin1 or the GAPDH loading control (lower 
panel). The effects of Pin1 siRNA inhibition on HIV nuclear entry and 
integration were determined by real time PCR quantification of HIV 
2-LTR circles (left panels) or Alu-LTR (right panels) respectively at day 
4 post-infection. HIV-infected PHA-IL2 activated (grey columns) or 
CCL19-treated (open columns) CD4+ T cells are shown. Each column 
represents the mean of three donors. Individual donors are shown as 
symbols. *p < 0.05; **p < 0.01
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integration occurred in either resting or activated CD4+ 
T cells. Using inverse PCR and cloning, as previously 
described [24], we identified unique integration sites 
following HIV infection of CCL19-treated (number of 
unique clones, n  =  247), PHA-IL2 activated (n  =  432) 
and unactivated CD4+ T cells (n =  133). We compared 
the integration sites to those previously published in total 
CD4+ T cells from HIV-infected patients on suppressive 
cART [25], and from random sites in the genome. Using 
this method, we could not assess the frequency of the 
specific clonal integration sites as recently reported [26, 
27], because we excluded analysis of integration sites that 
occurred more than once.
The distance from a series of genomic and epigenomic 
features are summarised as a heat map (Fig. 5). First, in 
all infection conditions, HIV preferentially integrated 
in actively transcribed genes (Additional file  4: Figure 
S4A, B) as previously reported for activated and resting 
CD4+ T cells [28, 29] and the Jurkat cell line [16]. Sec-
ond, the distance from the genomic and epigenomic fea-
tures in all in  vitro models was similar, and these sites 
Fig. 4 The NF-κB binding site in the HIV LTR is needed for efficient 
integration in CCL19-treated resting CD4+ T cells. a Mutations 
introduced into either or both NF-κB binding sites of the HIV LTR. The 
number of integrated HIV copies (b) and 2-LTR circles (c) per million 
cells 4 days following infection of unactivated, CCL19-treated and 
PHA-IL2 activated CD4+ T cells with wild type NL4-3 or NL4-3 contain-
ing mutations in the NF-κB binding sites, at both sites (ΔNF-κB1,B2) or 
either the first (ΔNF-κB1) or second (ΔNF-κB2) site alone. The columns 
represent the mean copy number and the individual donors are 
shown as different symbols. The detection limit for the Alu-LTR was 
300 copies/106 cells and is shown as a dashed line. The upper line and 
associated p value is for Kruskal–Wallis analysis of the four viruses and 
the lower line and p values shown as asterisks are for Mann–Whitney 
comparisons of two viruses or conditions. *p < 0.05, n = 4
Fig. 5 Distance of genomic features from the site of HIV integra-
tion. Following HIV infection of unactivated, CCL19-treated and 
PHA-IL2 activated CD4+ T cells, HIV integration sites were cloned, 
sequenced and mapped to the human genome. Genomic features 
were identified using the UCSC genome browser and the distance to 
the closest instance of each feature was determined. Comparison of 
the integration sites in each of the three in vitro conditions was made 
to integration sites previously described in CD4+ T cells from HIV-
infected patients on cART (n = 4) [24] and randomly selected sites 
on the genome (n = 10,000; random). The distance for each site was 
analysed and plotted as log mean distance. Blue represents increased 
and red represents decreased distance from the genomic feature. The 
labels on the y-axis are shown in Additional file 1: Table S1. The small 
boxes on the right of the figure describe the main features of the inte-
gration sites and are classified as genomic (grey), methylated (associ-
ated with elevated transcription, red; intermediate transcription, pink; 
and repression, blue) and acetylated (associated with promoters, pink; 
associated with TSS, red) features
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clustered separately from the patient-derived cells and 
random sites (Fig.  5). Finally, we found multiple dif-
ferences between the integration sites in the different 
in vitro conditions, after adjusting for multiple compari-
sons (Additional file 5: Table S1). 
Significant differences in integration sites between the 
different in vitro conditions were seen in the distance from 
the H2AZ, DNAse hypersensitivity site, Alu including Alu 
S, Alu J and Alu Y (Additional file 6: Figure S5A) and tran-
scriptional start sites (TSS), which are all highly transcrip-
tionally active regions. We saw no significant differences in 
the distance from CCCTC-binding Factor (T cell Factor, 
TCF), polymerase (pol) II, CpG and the majority of histone 
methylation and acetylation sites (Additional file 5: Table 
S1). For other genes such as Long Interspersed Nuclear 
elements (LINE 1), the integration sites in CCL19-treated 
infected cells were significantly closer than other in vitro 
conditions (Additional file 4: Figure S4C). This site tends 
to indicate gene rich regions. Based on the median dis-
tance from LINE 1, in CCL19-treated cells HIV showed a 
very strong preference to integrate in these sites, similar to 
patient derived cells. There was no association with culture 
conditions and proximity to RTE or CR1 but in CCL19-
treated cells, HIV integrated closer to L1 sites and more 
distant from L2 (Additional file  6: Figure S5B). For his-
tone methylation sites associated with intermediate tran-
scriptional activity, in CCL19-treated cells HIV integrated 
further away than in PHA-IL2 and unactivated cells. The 
exception in this group was H4R3me2, a methylation site 
initially thought to be involved in priming gene expression 
but more likely mediating global gene repression in T-cells 
[30] (Additional file 5: Table S1). Other histone methyla-
tion sites were distant from integration sites, except for 
H4K20me3, which is strongly associated with heterochro-
matin [31]. Integration of HIV in CCL19-treated cells, as 
well as in PHA-IL2 fully activated cells, had a strong pref-
erence for this region (Additional file 4: Figure S4C, Addi-
tional file 5: Table S1).
We used gene array analyses to look at the gene expres-
sion in different in vitro conditions and sought to deter-
mine if there was a relationship between expression of 
a specific gene and the site of integration. There was no 
significant difference between the three conditions in 
the level of expression of genes at the HIV insertion sites 
(Additional file 4: Figure S4A). The majority of the genes 
where HIV integration occurred, were involved in cel-
lular housekeeping activities (such as ubiquitin activity, 
nuclear transport, and nucleotide metabolism) and cell 
signalling pathways, and were expressed at similar levels 
in CCL19-treated and unactivated resting CD4+ T cells 
(Additional file 4: Figure S4B).
Finally, we have identified 152, 85 and 62 genes host-
ing integrated HIV in PHA-IL2, CCL19 and unactivated 
cells, respectively, of which 40 genes with insertion sites 
in two or more of the three cell populations (Additional 
file  7: Figure S6). Only two genes (TBCD; tubulin fold-
ing cofactor D and NSD1; nuclear receptor binding SET 
domain protein 1; Additional file 7: Figure S6, blue font) 
had been previously identified in infected CD4+ T cells 
from HIV-infected patients on cART [25–27, 32, 33]. We 
did find HIV integration in genes associated with mitosis 
and cancer, but these specific genes were not enriched in 
the three culture conditions (Additional file 7: Figure S6; 
red font). These data suggest that the selection for inte-
gration sites in CD4+ T cells from HIV infected patients 
on cART differs from in vitro infection of resting or acti-
vated CD4+ T cells.
Discussion
We have previously shown that multiple chemokines facil-
itate efficient HIV nuclear localization and integration in 
resting CD4+ T cells in  vitro [9]. Chemokines or HIV 
itself, via binding of gp120 to the co-receptor CXCR4, can 
activate the RhoA/Rac/cdc42 pathways and disrupt corti-
cal actin to allow passage of the pre-integration complex 
into the nucleus [3]. However, in purely resting CD4+ T 
cells, integration remains inefficient even if nuclear locali-
zation occurs [3, 9]. We now demonstrate that CCL19 
signalling, via the PI3K pathway and NF-κB, plays a key 
role in HIV integration in resting CD4+ T cells. HIV inte-
gration was reduced by inhibitors of NF-κB or upstream 
signalling pathways that reduce NF-κB activation. This is 
consistent with data from T cell lines, where low levels of 
NF-κB favored latent infection, while high levels of NF-κB 
favored productive infection [15].
We show that deletion of both NF-κB binding sites in 
the LTR eliminated HIV integration in CCL19-treated 
CD4+ T cells, but not in activated CD4+ T cells. Viruses 
with deletions or base-pair substitutions in the NF-κB 
enhancer of the LTR vary in replication competence 
in different in  vitro models [34, 35]. Other studies have 
shown a direct correlation between viral replication and 
the level of NF-κB protein expressed in the specific cell 
that was infected [35]. Mutation of GGG to CTC (or 
TCT) in the NF-κB sites in the LTR abrogated NF-κB 
binding [36] and resulted in lower HIV replication than 
wild type virus [37]. Although we found a small reduction 
in the replicative capacity of the NF-κB mutated viruses 
in PHA/IL2 activated CD4+ T cells, as measured by inte-
grated HIV DNA, there was no integration of mutant 
virus in CCL19-treated CD4+ T cells. Our data in a rest-
ing CD4+ T cell model of HIV latency shows a critical 
role for NF-κB in HIV integration in the CCL19-treated 
primary resting CD4+ T cells.
NF-κB, or indeed other transcription factors, could 
potentially increase efficient HIV integration in 
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CCL19-treated resting CD4+ T cells in several ways. 
First, in other retroviruses, direct interaction of tran-
scription factors with LTR enhancer sequences play a piv-
otal role in directing integration toward genomic regions 
rich in transcription factor binding sites [38]. In murine 
leukemia virus, transcription factors binding to the viral 
LTR enhancer may tether retroviral integrase and the 
pre-integration complex to transcriptionally active regu-
latory regions [39]. Second, NF-κB may facilitate HIV 
integration through its activity in homologous recombi-
nation and DNA repair, which is required for HIV inte-
gration [40]. The Lens epithelium–derived growth factor 
p75 splice variant (LEDGF) is a chromatin-binding pro-
tein that can direct HIV into active transcription units, 
and promotes the repair of DNA double-strand breaks 
by the homologous recombination repair pathway [41]. 
NF-κB may promote homologous recombination and 
DNA repair through interactions with Rad51, a key regu-
lator of the homologous recombination pathway of DNA 
repair [42], and with the Breast cancer 1-C-terminal 
binding protein 1 (BRCA1-CtIP) complex, which acceler-
ated Rad51 foci formation [42]. These observations, and 
our findings, suggest an important role for NF-κB activa-
tion in HIV integration, at least in resting CD4+ T cells 
that lack alternative transcription factors.
Other transcription factor binding sites, in particular 
AP-1, have been shown to be critical for the establish-
ment of latency amongst different subtypes of HIV [18]. 
Here we show that CCL19 could induce the signalling 
cascade upstream of AP-1, indicating that chemokine 
signalling may also maintain latent infection after inte-
gration has occurred. However, the importance of AP-1 
in maintaining HIV latency was not specifically tested in 
this model.
We also showed that akin to fully activated CD4+ T 
cells, CCL19 also induced signalling of the Ras/Raf/
MEK/JNK pathway. Activated JNK was shown to bind 
and phosphorylate HIV integrase, which then interact 
with Pin1 [23]. Pin1 was shown to play a crucial role in 
stabilizing integrase, in the form of a pre-integration 
complex, and prevent its degradation via the protea-
some pathway [23]. Thus inhibitors of the Ras/Raf/MEK/
JNK signalling pathway could lead to significant impair-
ment in HIV integration and 2-LTR circles formation in 
both CCL19 and PHA-IL2 treated CD4+ T cells. This is 
further supported by evidence that knockdown of Pin1 
led to a similar effect as using inhibitors of the Ras/Raf/
MEK/JNK signalling pathway on both HIV integration 
and 2-LTR circles formation. The reduction of 2-LTR cir-
cles to levels found in unactivated cells in the presence 
of PI3K or NF-κB inhibitors was less clear. One possible 
explanation was that phosphorylated NF-κB binds to its 
binding sites in the LTR and facilitates nuclear entry of 
the pre-integration complex (Fig. 4 and [43]), thus inhi-
bition of NF-κB signalling could lead to a reduction of 
nuclear entry and subsequently affect both the level of 
integration and 2-LTR circles.
Finally, we show that the site of HIV integration differs 
between cells with differing activation states at the time 
of HIV infection. The majority of integration sites were 
within active transcriptional units, as previously shown 
for patient derived cells and other models of in  vitro 
infection [24, 44, 45]. However, CCL19-treated resting 
CD4+ T cells had a pattern of integration that differed 
significantly from the other in vitro conditions, suggest-
ing HIV integration site selection may depend on the 
balance of transcription factors, including NF-κB, at the 
time of infection. Differences in integration site may also 
contribute to the varied response to latency activators 
using different in  vitro models of latent infection [10]. 
Our findings are in contrast to a recent study of multiple 
in  vitro models of latency, where integration sites were 
associated with differences in virus expression in individ-
ual models, but integration sites and associated genomic 
features were not predictive across different models 
of latency [45]. It is important to note that the analysis 
used for our study was different because we compared 
infected resting and activated cells, rather than compar-
ing expressed and inducible infection in different mod-
els of latency. In our method of integration site analysis 
we considered only unique sites in each condition and 
were therefore unable to show over-representation of the 
particular integration sites recently reported for BACH 
and other genes using CD4+ T cells from HIV-infected 
patients on cART [25–27, 32, 33].
Conclusions
We show that activation of NF-κB and the NF-κB bind-
ing site of the HIV LTR enhancer promoter are critical 
for efficient HIV integration in CCL19-treated resting 
CD4+ T cells. CCL19 signalling increases the stability 
of HIV integrase, protects it from degradation, which 
allows subsequent integration and establishment of 
latency. Furthermore, we show significant differences in 
integration sites following HIV infection of unactivated, 
CCL19-treated, and fully activated CD4+ T cells. These 
findings have implications for strategies needed to pre-
vent the establishment, and potentially reverse, latent 
infection.
Methods
Isolation of CD4 T cells
Peripheral blood mononuclear cells (PBMC) were iso-
lated from buffy coats obtained from the Australian Red 
Cross Blood Service (Melbourne, Australia). Resting 
CD4+ T cells were isolated by magnetic bead depletion 
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and cell sorting as previously described [8]. The result-
ing T cells consisted predominantly of naïve and central 
memory T cells [46] and purity was routinely >95 %, as 
assessed by flow cytometry.
Cell lysis, immunoblotting (IB) and immunoprecipitation 
(IP)
To measure the effect of CCL19 on activation of the 
PI3K signalling pathway, we first determined the dose 
and kinetics of CCL19 on key signalling proteins phos-
phorylation in resting CD4+ T cells. In brief, freshly iso-
lated resting CD4+ T cells were cultured overnight in 
RF1 [RPMI1640 media supplemented with 1× penicil-
lin–streptomycin–glutamine (Life Technologies, Carls-
bad, CA) and 1  % heat-inactivated fetal bovine serum 
(Bovogen Biologicals, Melbourne, Australia)]. On the 
following day, five million viable cells per condition was 
stimulated with various doses of CCL19 (30, 100, 200 
and 300  nM) for exactly 5 or 15  min and immediately 
lysed with RIPA buffer (1  % NP40, 0.5  % SDS, 1  mM 
DTT, 10  mM Tris–HCl pH 7.6, 150  mM NaCl, 2  mM 
EDTA) containing Halt protease and phosphatase inhib-
itor cocktail (Thermo Fisher Scientific, Waltham, MA). 
Unstimulated or phorbol 12-myristate 13-acetate (PMA, 
10 µg/ml Sigma-Aldrich, St. Louis MO) and ionomycin 
(2  µM, Sigma-Aldrich) stimulated cells were used as 
controls.
Protein concentrations of cell lysates were measured 
by the Bradford protein assay (Bio-Rad, Hercules, CA). 
Total cell lysates (50  μg) were resolved on a 10  % SDS-
polyacrylamide gel, transferred onto nitrocellulose 
membrane, and processed further for immunobloting 
as previously described [9]. The membrane was sequen-
tially probed with 1:1000 of anti-p-NF-κB (ser529, BD 
Biosciences, San Jose, CA), anti-p-Akt, anti-p-JNK, 
anti-p-ERK1/2, anti-p-p38, and anti-glyceraldehyde 
3-phosphate dehydrogenase (GAPDH; all from Cell sig-
nalling Technologies, Danvers, MA), and re-probed with 
either horseradish peroxidase-conjugated anti-mouse or 
anti-rabbit secondary antibodies (Cell Signalling Tech-
nologies). The signal density was analysed using elec-
trochemiluminescence (ECL) plus Western blotting 
detection reagents (GE Healthcare, UK) and MF-Chemi-
BIS chemiluminescence imaging (DNR Bio-Imaging sys-
tems, Jerusalem Israel).
Immunoprecipitation experiments were performed 
using 200 µg of total cell lysate from CCL19 or PHA-IL2_
treated CD4+ T cells in the presence or absence of JNK 
inhibitor, SP600125 (10  µM, Sigma-Aldrich). Primary 
antibodies to Pin1 (Santa Cruz Biotechnology Inc, Dallas, 
TX) was added and incubated overnight at 4 °C followed 
by the addition of protein-G-sephrose beads (Genscript, 
Piscataway, NJ) for another 3 h. After washing the beads, 
the samples were subjected to IB analysis using anti-HIV 
integrase antibody (Abcam, Cambridge, UK).
Inhibition of PI3K signalling pathway using 
pharmacological inhibitors
Freshly isolated purified CD4+ T cells were rested over-
night in RF1 and incubated in the presence or absence of 
either PI3K inhibitors LY294002 (50 µM) and Wortman-
nin (100  nM); p38 inhibitor SB203580 (5  µM); MEK1/
ERK1/2 inhibitor PD980509 (50  µM); JNK inhibitor 
SP600125 (10  µM, All from Sigma-Aldrich); NF-κB 
inhibitors SC-514 (100  µM) and Bay 11-7082 (10  µM, 
Calbiochem, San Diego, CA); or AP-1 inhibitor SR11032 
(1  µM, Tocris Biosciences, Bristol, UK) for 1  h. Cells (5 
million) were treated with 100 nM of CCL19 for 15 min, 
lysed and immunoblotted as described above. Unstimu-
lated or phorbol 12-myristate 13-acetate (PMA, 10  µg/
ml Sigma-Aldrich) and ionomycin (2 µM, Sigma-Aldrich) 
stimulated cells were used as controls. Protein intensity 
was analysed using densitometry of gel images using FIJI 
software [47].
Plasmids and virus production
293T cells (ATCC, Manassas, VA) were transfected 
according to the manufacturer’s instructions (FuGene; 
Roche Diagnostics, Indianapolis, IN) with the plasmid 
coding for CXCR4 (X4)-using virus NL4-3 (kindly sup-
plied by Prof. Damian Purcell, University of Melbourne, 
Australia). Viral plasmids with mutations in the NF-κB 
binding sites in the HIV long terminal repeat (LTR) were 
kindly provided by Dr. Monsef Benkirane (Institute of 
Human Genetics, Montpellier, France [48]) and included 
those with either a single mutation (GGG  →  CTC) at 
position −105 (site 1) or position −92 (site 2), or at both 
sites (double mutant) [49]. Following transfection, cul-
ture supernatants were concentrated over sucrose gradi-
ents and assessed for reverse transcriptase (RT) activity 
[8].
Infection of resting CD4+ T cells
Resting CD4+ T cells were isolated by magnetic bead 
depletion and cell sorting, as previously described [8]. 
Purified cells were incubated with CCL19 (30  nM) for 
24  h prior to infection. When pharmacological inhibi-
tors of PI3K signalling were used, inhibitors were added 
1  h prior to the addition of CCL19. Cells activated for 
2 days with phytohemagglutinin (PHA, 10 μg/ml; Sigma) 
and IL2 (10  IU/ml, Roche Diagnostics) or left unstimu-
lated were used as controls. Cells were then infected with 
NL4-3 virus, or with NL4-3 that had a mutation in one or 
both NF-κB binding sites at 1 reverse transcriptase (RT) 
count per minute (CPM)/cell for 2 h at 37 °C and washed 
before further culture with IL2 (1 IU/ml).
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Cytotoxicity assay
To address the toxicity of the pharmacological agents 
used, freshly isolated resting CD4+ T cells were treated 
with the same dose of pharmacological inhibitors in the 
presence of CCL19 (30  nM) for 48  h. Cells were then 
washed and cultured for a further 72 h. The percentage 
of viable cells on day 2 and day 5 was determined by flow 
cytometry using live fixable viability dye eFluor® 780 
(eBioscience, San Diego, CA), according to manufactur-
er’s instruction.
Quantification of HIV infection
Following infection, RT was quantified in cell culture 
supernatant as previously described [8]. Integrated HIV 
DNA and 2-LTR circles were quantified using real time 
PCR (iCycler, Bio-Rad, Hercules, CA) as previously 
described [9, 50].
Small interfering (si)RNA nucleofection
Resting CD4+ T cells were transfected with peptidyl pro-
lyl-isomerase (Pin1) specific siRNA (sc-36230-SH; Santa 
Cruz, Biotechnology Inc, Dallas, TX) or control (scram-
bled) siRNA (sc-37007, Santa Cruz Biotechnology Inc), 
at 100  pmol per reaction using nucleofection (Amaxa 
Human T cell Nucleofector kit, Lonza, Cologne, Ger-
many) according to the manufacturer’s instruction. Pin1 
siRNA sequences: 5′-GUCAGAUGCAGAAGCCAUU-3′, 
5′-CCGAAUUGUUUCUAGUUAG-3′, and 5′-UCCU-
CUGUUCAGUCGCAAA-3′. Knockdown of Pin1 protein 
was confirmed by Immunoblot using anti-Pin1 antibody 
(Santa Cruz Biotechnology Inc). Transfected cells were 
maintained in RPMI 1640 with 10 % Fetal calf serum for 
up to 48 h and stimulated with either PHA-IL2 or CCL19 
prior to HIV infection or analysed by IB.
Cloning and sequencing of HIV integration sites
Resting CD4+ T cells were activated with PHA-IL2, 
CCL19, or left unactivated before infection with HIV. 
Cells were harvested at day 4 post infection and the lev-
els of viral integration were assessed by real-time PCR 
assay for Alu-LTR [50]. The identification of HIV inte-
gration sites was determined by an inverse PCR assay as 
previously described [24]. The integration site sequences 
were mapped onto the human genome using University 
of California Santa Cruz (UCSC) Genome Bioinformatics 
database. All the genomic feature data sets were down-
loaded from the UCSC genome database. The pattern of 
these features was compared between the in vitro condi-
tions and CD4+ T cells from HIV-infected patients on 
antiretroviral therapy from published data [25]. To assess 
patterns in relation to genomic features, such as DNA 
methylation and/or acetylation pattern, the distance from 
these genomic features was calculated using Genomic 
Hyperbrowser (http://hyperbrowser.uio.no/hb/). Gene 
expression in the in  vitro infected cells was determined 
using gene array analysis [51]. Cells were activated with 
CCL19 for either 6  h or 72  h before infection, gene 
expression from the two time-points were compared to 
unactivated or PHA-IL2 activated cells.
Statistical analysis
Graphpad Prism was used for statistical analyses and 
preparing plots. A Kruskal–Wallis test was used for com-
parisons between groups and a Mann–Whitney test for 
analysis within groups. For comparisons between groups 
either a Student’s t test or a Mann–Whitney U test was 
used. Normalization was performed by log transforma-
tion before analysis.
The statistical program R [51] was used for analysis of 
gene arrays, cluster analysis and heatmap generation. A 
Student’s t test or Mann–Whitney test was used for com-
parisons between populations and p  <  0.05 was consid-
ered significant.
For the site of integration, a Fisher’s exact test was 
used to determine the statistical significance between the 
groups when examining the proportion of integration 
sites that were near or far from a specific genomic fea-
ture. In addition, we treated the median distance of inte-
gration sites as a measure of association for that genomic 
feature. Since the populations of integration sites failed 
the normality tests, we used a non-parametric Kruskal–
Wallis ANOVA to determine significance. We then used 
a Dunn’s test with Bonferroni correction to determine 
the difference between each group.
Additional files
Additional file 1: Figure S1. Signalling pathways downstream of CCR7. 
Schematic representation of the signalling pathways activated by PI3K 
and Ras following chemokine ligation. The site of action and names of 
specific inhibitors are shown as red lines. Figure is based on [20, 52–54]; 
and the KEGG Chemokine signalling pathway; http://www.genome.jp/
kegg-bin/show_pathway?map04062.
Additional file 2: Figure S2. Dose response of CCL19 on resting CD4+ 
T cells. Resting CD4+ T cells were incubated with various concentrations 
of CCL19 for 5 minutes (A) or 15 minutes (B) and the level of intracellular 
phosphorylated proteins examined. Cell lysates were assessed by immu-
nobloting using antibody to phosphorylated Akt (pAkt), pNF-κB, pERK, 
pJNK and loading control GAPDH. Cells treated with PMA and Ionomycin 
was used as a positive control. Data represent immunoblots of two inde-
pendent experiments.
Additional file 3: Figure S3. Cytotoxicity of signalling inhibitors on 
CD4+ T cells. Resting CD4+ T cells were treated with various inhibitors (see 
“Methods” for concentrations used) in the presence of CCL19 and incu-
bated for 48 h. Cells were then washed and cultured for another 72 h. Cell 
viability was determined using live/dead staining and analysed by flow 
cytometer. Data represents mean ± SD of two independent experiments.
Additional file 4: Figure S4. Integration site selection and gene activa-
tion in chemokine treated cells. A, Gene expression was determined by 
Illumina bead array in unactivated, CCL19-treated or PHA-IL2 activated 
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